
A diabetes drug built to control blood sugar just proved it can stop heart attacks and strokes in people who don’t even have diabetes.
Quick Take
- A massive trial found weekly semaglutide cut heart attacks, strokes, and cardiovascular deaths in overweight adults with existing heart disease.
- The Food and Drug Administration (FDA) used that trial to approve Wegovy for heart-risk reduction, not just weight loss.
- A separate trial showed tirzepatide helped patients with obesity and a common type of heart failure feel and function better.
- Both drugs remain approved for specific, high-risk patient groups, not as blanket heart protection for everyone with extra weight.
- Cost and insurance limits are shaping who actually gets these benefits in real life.
The Trial That Changed The Conversation
The SELECT trial enrolled 17,604 adults who were overweight or obese, had existing heart disease, but did not have diabetes. Over nearly four years, those taking weekly semaglutide 2.4 milligrams had fewer heart attacks, strokes, and cardiovascular deaths than those on a placebo. Researchers tracked these as hard clinical events, not just lab numbers or scale readings.
Novo Nordisk, the drug’s maker, reported a 20% reduction in major cardiovascular events compared to placebo. The FDA’s own review called SELECT the first trial to show a weight-loss drug could lower these serious heart outcomes. That finding carried enough weight for regulators to expand Wegovy’s approved use beyond weight management alone.
A Second Heart Drug Emerges For A Different Problem
A separate trial called SUMMIT looked at tirzepatide in patients with obesity and a specific kind of heart failure called HFpEF, where the heart’s main pumping chamber stiffens. Patients taking tirzepatide reached the trial’s combined endpoint of cardiovascular death or worsening heart failure far less often than those on placebo, 9.9% versus 15.3%.
The improvement came mostly from fewer hospital-level worsening-heart-failure events rather than fewer deaths. Patients also reported walking farther in six minutes and scoring better on standard heart-failure quality-of-life questionnaires. They lost roughly 11 to 12 percent more weight than the placebo group, suggesting the benefit runs alongside, not just because of, pounds shed.
What The Approved Label Actually Covers
Both trials targeted narrow groups. SELECT studied people with established heart disease and no diabetes. SUMMIT studied people with obesity and a specific heart-failure diagnosis. Neither trial tested the drugs in healthy-weight people or those without diagnosed heart problems, so neither result proves these medicines prevent heart disease in the general population.
Novo Nordisk celebrated the cardiovascular-risk-reduction approval for Wegovy as a milestone, and it genuinely is one. But the approval covers a defined population with overweight or obesity plus existing cardiovascular disease. It is not a green light to treat every patient carrying extra weight as if they’re automatically getting the same heart protection.
The Price Tag Behind The Promise
Clinical results mean little if patients can’t stay on the medication. Real-world data show persistence drops fast: one large claims study found only 46.3% of patients were still on their GLP-1 drug at 180 days. Among 225,000 patients checked for insurance coverage, fewer than 4% got semaglutide approved without extra paperwork hurdles.
GLP-1-based therapies have transformed the treatment of obesity and type 2 diabetes, with additional indications for cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities. As more patients start these medications, clinicians need to consider how… pic.twitter.com/RPIgXpJxhp
— Medscape (@Medscape) November 15, 2026
Employers are feeling the squeeze too. The share of companies covering GLP-1 drugs for weight loss fell from 72% in 2025 to 60% in 2026 as pharmacy costs climbed toward a quarter of total health spending. A national working paper even found that over five years, these drugs did not lower overall medical spending and modestly raised outpatient costs. That’s the real tension conservatives and patients alike should watch: strong science running into a healthcare system struggling to pay for it. Good medicine only helps the people who can actually get and afford it, and right now, too many can’t.
Sources:
youtube.com, nejm.org, acc.org, novonordisk-us.com, accessdata.fda.gov, nber.org, link.springer.com, cvshealth.com













